MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$10,246K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable, accrued expens...
Prepaid expenses and other curre...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchase of product rights
Net income (loss)
Accounts receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Investment loss (gain) from investment in eton
-
-
0
-
Impairment of intangible assets
-
-
0
-
Net income (loss)
-17,270
-27,602
6,626
1,020
Depreciation and amortization of property, plant and equipment and software development costs
460
455
464
490
Amortization of intangible assets
5,527
5,129
4,315
4,224
Noncash lease expense
197
192
188
583
Acquisition of melt pharmaceuticals
-
-
4,358
-
(recovery of) provision for credit losses
-100
-195
-80
208
Amortization of debt issuance costs, discount and premium, net
400
451
358
1,128
Loss on extinguishment of debt
-
-
0
-7,750
Loss on disposal of equipment
-
-
-13
-
Stock-based compensation
3,788
3,837
3,800
3,271
Accounts receivable
17,200
-9,831
33,215
-1,014
Inventories
414
2,973
689
1,282
Prepaid expenses and other current assets
-4,009
-346
1,525
1,327
Accounts payable, accrued expenses, accrued rebates and copay assistance
8,544
3,377
22,441
-3,040
Accrued payroll and related liabilities
2,347
-1,201
914
2,694
Deferred revenue and customer deposits
-43
-639
443
254
Net cash (used in) provided by operating activities
-9,755
-8,992
8,411
16,588
Net proceeds on sale of investment in eton pharmaceuticals
-
-
0
-
Investment in patent and trademark assets
43
9
-22
-147
Acquisition of melt pharmaceuticals
-
-
4,358
-
Purchase of product rights and related patents
-
-
-377
162
Purchase of product rights
36,000
-18,000
-
-
Purchases of property, plant and equipment
491
194
341
210
Net cash used in investing activities
-534
-18,203
-4,730
-225
Net proceeds from 8.625 notes payable, net of commissions
0
49,000
0
-
Net proceeds from public offering
-
-
0
-
Proceeds from new debt, net of costs
-
-
-
244,375
Proceeds from public offering of common stock, net of offering costs
-
-
0
-
Payment of debt issuance costs
442
113
46
1,581
Proceeds from new debt, net of costs
-
-
244,375
-
Repayment of notes payable, including exit costs
-
-
-
230,901
Repayment of notes payable, inclusive of costs
-
-
230,903
-
Payment of payroll taxes upon vesting of psus, rsus and exercise of stock options
-
-
5,176
7,091
Proceeds from exercise of stock options
811
25
180
162
Payment of payroll taxes upon exercise and issuance of equity awards
835
-
-
-
Net cash provided by (used in) financing activities
-466
48,912
-5,044
4,964
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
-
-
-1,363
-
Net change in cash and cash equivalents
-10,755
21,717
-1,363
21,327
Cash and cash equivalents, beginning of period
94,644
72,927
74,290
47,247
Cash and cash equivalents, end of period
83,889
94,644
72,927
74,290
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net change in cash
and cash...
-$10,755K
(-288.16%↓ Y/Y)
Accounts payable,
accrued expenses,...
$8,544K
(135.59%↑ Y/Y)
Amortization of intangible
assets
$5,527K
(-34.61%↓ Y/Y)
Prepaid expenses and
other current assets
-$4,009K
(-6.17%↓ Y/Y)
Stock-based compensation
$3,788K
(-30.25%↓ Y/Y)
Accrued payroll and
related liabilities
$2,347K
(187.84%↑ Y/Y)
Depreciation and
amortization of property,...
$460K
(-52.13%↓ Y/Y)
Amortization of debt issuance
costs, discount and...
$400K
(-84.40%↓ Y/Y)
Noncash lease expense
$197K
something is missing
$36,000K
Proceeds from exercise of
stock options
$811K
(548.80%↑ Y/Y)
Net cash (used in)
provided by operating...
-$9,755K
(-151.71%↓ Y/Y)
Net cash used in
investing activities
-$534K
(-5.74%↓ Y/Y)
Net cash provided by
(used in) financing...
-$466K
(96.31%↑ Y/Y)
Canceled cashflow
$25,272K
Canceled cashflow
$36,000K
Canceled cashflow
$811K
Net income (loss)
-$17,270K
(-35.08%↓ Y/Y)
Purchase of product
rights
$36,000K
Payment of payroll taxes
upon exercise and...
$835K
Accounts receivable
$17,200K
(146.22%↑ Y/Y)
Inventories
$414K
(-51.29%↓ Y/Y)
(recovery of) provision
for credit losses
-$100K
(-129.41%↓ Y/Y)
Deferred revenue and
customer deposits
-$43K
(-191.49%↓ Y/Y)
Purchases of property,
plant and equipment
$491K
(46.13%↑ Y/Y)
Investment in patent and
trademark assets
$43K
(-74.56%↓ Y/Y)
Payment of debt issuance
costs
$442K
Buy us a coffee
HARROW, INC. (HROW)
HARROW, INC. (HROW)